MSK Department of Medicine shared on X:
“Over the next three days, learn about the latest myeloma research advances during IMS26 poster sessions!
Join Hamza Hashmi and Carlyn Tan to explore their latest findings:
•Real-world analysis on early vs. late line cilta-cel for R/R multiple myeloma
• Pilot study on romosozumab for myeloma-related bone disease in postmenopausal patients
• Prior BCMA exposure outcomes with teclistamab and elranatamab for R/R multiple myeloma
• Hematology-oncologists’ perspectives on an on-body injector for subcutaneous dosing in multiple myeloma.
Poster sessions: Sept. 23, 24, & 25 | 12 p.m. BT | Hall 4.”
Other articles about IMS26 on OncoDaily.